Dopamine Signaling Controls Pathological Tau

Principal Investigator

VA Puget Sound Health Care System (VAPSHCS)
Seattle, WA
Acknowledgement
This grant is made possible in part by a bequest from the John A. Beaty Trust.

Project Goals

A number of neurodegenerative disorders feature tau deposits, including Alzheimer’s disease. These abnormal aggregations of tau protein can cause age-dependent neurodegeneration. We have identified a class of drugs that prevent abnormal tau formation in animal models of Alzheimer’s disease. The goal of this project is to understand how these experimental drugs prevent abnormal tau so that we can develop these drugs further, ultimately setting the stage for clinical trials in Alzheimer’s patients.

First published on: July 09, 2014

Last modified on: May 13, 2024